Parvovirus-Related Arthritis

  • Martin Brom
  • Carlos Edgardo Perandones


Parvovirus B19 is a small virus with worldwide distribution and high infectivity rates, that affects mainly school-aged children, but previously non-infected adults are also susceptible. After infection, patients develop life-lasting neutralizing antibodies.

Infected patients may present with a myriad of symptoms, ranging between an asymptomatic state and flu-like disease to several manifestations of diverse severity, including fetal complications.

The most frequent manifestation of the disease in children is erythema infectiosum (fifth disease), while adults, especially woman, usually present with arthritis. Nevertheless, there is controversy on a possible role of Parvovirus B19 as a trigger for rheumatic diseases such as rheumatoid arthritis, lupus, vasculitis, and myositis, among others.


Parvovirus B19, Human (D016732) Erythema Infectiosum (D016731) Arthritis, Infectious (D001170) Anemia, Aplastic (D000741) Red-Cell Aplasia, Pure (D012010) Hepatitis, Viral, Human (D006525) Myocarditis (D009205) Hydrops Fetalis (D015160) Arthritis, Rheumatoid (D001172) Arthritis, Juvenile (D001171) Encephalitis, Viral (D018792) Lupus Erythematosus, Systemic (D008180) Vasculitis (D014657) RS3PE Remitting Seronegative Symmetrical Synovitis with Pitting Edema 



Anti-citrullinated protein Antibodies


Chronic Fatigue Syndrome


Central Nervous System


C Reactive Protein


Cerebrospinal Fluid


Erythema Infectiosum


Erythrocyte Sedimentation Rate




Human Bocavirus 1 to 4


Human Leukocitary Antigen


Interferon γ




Intrauterine Transfusion


Juvenile Idiopathic Arthritis


Kilo Dalton


Non-Immune Hydrops Fetalis




Open Reading Frame


Polymerase Chain Reaction


Papular Purpuric Gloves and Socks Syndrome


Pure Red Cell Aplasia


Parvovirus B19


Rheumatoid Arthritis


Systemic Lupus Erythematosus


Secreted Phospholipase A2


Signal Transducer and Activator of Transcription 3


Transient Aplastic Crisis


Tissular Grow Factor β


Tumor Necrosis Factor α


  1. 1.
    Tschamer A. Über örtliche Röteln. Jahrb f Kinder. 1889;(29):372–9.Google Scholar
  2. 2.
    Ager EA, Chin TDY, Poland JD. Epidemic erythema infectiosum. N Engl J Med. 1966;275(24):1326–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Cossart YE, Cant B, Field AM, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;305(7898):72–3.CrossRefGoogle Scholar
  4. 4.
    Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anemia. Lancet. 1981;317(8221):664–5.CrossRefGoogle Scholar
  5. 5.
    Serjeant GR, Mason K, Topley JM, Serjeant BE, Pattison JR, Jones SE, et al. Outbreak of aplastic crises in sickle cell anemia associated with parvovirus-like agent. Lancet. 1981;318(8247):595–7.CrossRefGoogle Scholar
  6. 6.
    Anderson M, Jones S, Fisher-Hoch S, Lewis E, Hall S, Bartlett CL, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet. 1983;321(8338):1378.CrossRefGoogle Scholar
  7. 7.
    White DG, Mortimer PP, Blake DR, Woolf AD, Cohen BJ, Bacon PA. Human parvovirus arthropathy. Lancet. 1985;325(8426):419–21.CrossRefGoogle Scholar
  8. 8.
    Reid DM, Brown T, Reid TMS, Rennie JAN, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985;325(8426):422–5.CrossRefGoogle Scholar
  9. 9.
    Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262(5130):114–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Qiu J, Söderlund-Venermo M, Young NS. Human parvoviruses. Clin Microbiol Rev. 2017;30(1):43–113.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest. 1992;89(6):2023–9.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol. 2002;76(4):2014–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol. 1998;72(4):3018–28.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Hsu TC, Tzang BS, Huang CN, Lee YJ, Liu GY, Chen MC, et al. Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. Clin Exp Immunol. 2006;144(1):152–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol. 2002;76(11):5395–403.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Duechting A, Tschope C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, et al. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol. 2008;82(16):7942–52.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Brown KE, Hibbs JR, Gallinella G, Anderson SM, Lehman ED, McCarthy P, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330(17):1192–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Cooling LL, Koerner TA, Naides SJ. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis. 1995;172(5):1198–205.PubMedCrossRefGoogle Scholar
  19. 19.
    Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood. 2003;102(12):3927–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. 2005;106(10):3449–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Wong S, Zhi N, Filippone C, Keyvanfar K, Kajigaya S, Brown KE, et al. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol. 2008;82(5):2470–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002;76(18):9124–34.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79(13):8230–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci. 2005;102(36):12891–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152(2):257–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet. 1988;2(8621):1159–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. Human parvovirus B19: a review. Acta Virol. 2014;58(03):199–213.PubMedCrossRefGoogle Scholar
  28. 28.
    Admani S, Jinna S, Friedlander SF, Sloan B. Cutaneous infectious diseases: kids are not just little people. Clin Dermatol. 2015;33(6):657–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Drago F, Ciccarese G, Broccolo F, Javor S, Parodi A. Atypical exanthems associated with parvovirus B19 (B19V) infection in children and adults. J Med Virol. 2015;87(11):1981–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Katta R. Parvovirus B19: a review. Dermatol Clin. 2002;20(2):333–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Dereure O, Montes B, Guilhou JJ. Acute generalized livedo reticularis with myasthenia-like syndrome revealing parvovirus B19 primary infection. Arch Dermatol. 1995;131(6):744–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Lobkowicz F, Ring J, Schwarz TF, Roggendorf M. Erythema multiforme in a patient with acute human parvovirus B19 infection. J Am Acad Dermatol. 1989;20(5):849–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Naides SJ, Piette W, Veach LA, Argenyi Z. Human parvovirus B19-induced vesiculopustular skin eruption. Am J Med. 1988;84(5):968–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Cioc AM, Sedmak DD, Nuovo GJ, Dawood MR, Smart G, Magro CM. Parvovirus B19 associated adult Henoch Schonlein purpura. J Cutan Pathol. 2002;29(10):602–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kok RH, Wolfhagen MJ, Klosters G. A syndrome resembling thrombotic thrombocytopenic purpura associated with human parvovirus B19 infection. Clin Infect Dis. 2001;32(2):311–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Aktepe OC, Yetgin S, Olcay L, Özbek N. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2004;21(5):421–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Magro CM, Dawood MR, Crowson AN. The cutaneous manifestations of human parvovirus B19 infection. Hum Pathol. 2000;31(4):488–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Woolf AD. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149(5):1153.PubMedCrossRefGoogle Scholar
  39. 39.
    Seishima M, Kanoh HIT. The spectrum of cutaneous eruptions in 22 patients with isolated serological evidence of infection by parvovirus B19. Arch Dermatol. 1999;135(12):1556–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Balfour HH. Erythema Infectiosum (fifth disease): clinical review and description of 91 cases seen in an epidemic. Clin Pediatr (Phila). 1969;8(12):721–7.CrossRefGoogle Scholar
  41. 41.
    Vafaie J, Schwartz RA. Erythema infectiosum. J Cutan Med Surg. 2005;9(4):159–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown KE. 149 - human parvoviruses, including parvovirus B19V and human bocaparvoviruses. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier; 2015. p. 1840–7.Google Scholar
  43. 43.
    Balfour HH. Fifth disease: full fathom five. Am J Dis Child. 1976;130(3):239–40.PubMedGoogle Scholar
  44. 44.
    Harms M, Feldmann R, Saurat J-H. Papular-purpuric “gloves and socks” syndrome. J Am Acad Dermatol. 1990;23(5):850–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Bagot M, Revuz J. Papular-purpuric “gloves and socks” syndrome: primary infection with parvovirus B19? J Am Acad Dermatol. 1991;25(2):341.PubMedCrossRefGoogle Scholar
  46. 46.
    Feldmann R, Harms M, Saurat J-H. Papular-purpuric “gloves and socks” syndrome: not only parvovirus B19. Dermatology. 1994;188(2):85–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric “gloves and socks” syndrome in children and adolescents. Pediatr Infect Dis J. 2009;28(3):250–2.PubMedCrossRefGoogle Scholar
  48. 48.
    Aractingi S, Bakhos D, Flageul B, Vérola O, Brunet M, Dubertret L, et al. Immunohistochemical and virological study of skin in the papular-purpuric “gloves and socks” syndrome. Br J Dermatol. 1996;135(4):599–602.PubMedCrossRefGoogle Scholar
  49. 49.
    Veraldi S, Rizzitelli G, Scarabelli G, Gelmetti C. Papular-purpuric “gloves and socks” syndrome. Arch Dermatol. 1996;132(8):975–7.PubMedCrossRefGoogle Scholar
  50. 50.
    McNeely M, Friedman J, Pope E. Generalized petechial eruption induced by parvovirus B19 infection. J Am Acad Dermatol. 2005;52(5):S109–13.PubMedCrossRefGoogle Scholar
  51. 51.
    Sklavounou-Andrikopoulou A, Iakovou M, Paikos S, Papanikolaou V, Loukeris D, Voulgarelis M. Oral manifestations of papular-purpuric “gloves and socks” syndrome due to parvovirus B19 infection: the first case presented in Greece and review of the literature. Oral Dis. 2004;10(2):118–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Grilli R, Izquierdo MJ, Fariña MC, Kutzner H, Gadea I, Martin L, et al. Papular-purpuric “gloves and socks” syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol. 1999;41(5):793–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin N Am. 2009;35(1):95–110.CrossRefGoogle Scholar
  54. 54.
    Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol. 2000;12(4):289–94.PubMedCrossRefGoogle Scholar
  55. 55.
    Tello-Winniczuk N, Díaz-Jouanen E, Díaz-Borjón A. Parvovirus B19-associated arthritis: report on a community outbreak. J Clin Rheumatol. 2011;17(8):449–50.PubMedCrossRefGoogle Scholar
  56. 56.
    Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. J Pediatr. 1993;122(2):186–90.PubMedCrossRefGoogle Scholar
  57. 57.
    Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis. 2000;59(9):672–83.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586–97.PubMedCrossRefGoogle Scholar
  59. 59.
    Mauermann M, Hochauf-Stange K, Kleymann A, Conrad K, Aringer M. Parvovirus infection in early arthritis. Clin Exp Rheumatol. 2016;34(2):207–13.PubMedGoogle Scholar
  60. 60.
    Naciute M, Mieliauskaite D, Rugiene R, Nikitenkiene R, Jancoriene L, Mauricas M, et al. Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J Gen Virol. 2016;97(12):3302–12.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Altschuler EL. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet. 1999;354(9183):1026–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Page C, François C, Goëb V, Duverlie G. Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses. J Clin Virol. 2015;72(2015):69–74.PubMedCrossRefGoogle Scholar
  63. 63.
    Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A. 1998;95(July):8227–32.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Kakurina N, Kadisa A, Lejnieks A, Mikazane H, Kozireva S, Murovska M. Use of exploratory factor analysis to ascertain the correlation between the activities of rheumatoid arthritis and infection by human parvovirus B19. Medicina. 2015;51(1):18–24.PubMedCrossRefGoogle Scholar
  65. 65.
    Kerr JR. Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J Vet Med Ser B Infect Dis Vet Public Heal. 2005;52(7–8):335–9.CrossRefGoogle Scholar
  66. 66.
    Tsay GJ, Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol. 2006;72(11):1453–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Ray NB, Nieva DR, EA S, Khalkhali-Ellis Z, Naides SJ. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum. 2001;44(7):1582–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol. 1998;28(3):936–48.PubMedCrossRefGoogle Scholar
  69. 69.
    Kerr JR, Mattey DL, Thomson W, Poulton KV, Ollier WER. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis. 2002;186(4):447–52.PubMedCrossRefGoogle Scholar
  70. 70.
    Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, Hutchinson IV, et al. Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol. 2001;82(12):3011–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis. 2006;193(4):582–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Kerr JR, Cunniffe VS, Kelleher P, Coats AJS, Mattey DL. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol. 2004;74(1):147–55.PubMedCrossRefGoogle Scholar
  73. 73.
    Kerr JR. Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol. 2003;56(10):725–7.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Naciute M, Mieliauskaite D, Rugiene R, Maciunaite G, Mauricas M, Murovska M, et al. Parvovirus B19 infection modulates the levels of cytokines in the plasma of rheumatoid arthritis patients. Cytokine. 2017;96:41–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Kerr JR, Cartron JP, Curran MD, Elliott JRM, Mollanj RAB, Hospital BC, et al. A study of the role of parvovirus B19 in rheumatoid arthritis. Br J Rheumatol. 1995;34(9):809–13.PubMedCrossRefGoogle Scholar
  76. 76.
    Hokynar K, Brunstein J, Söderlund-Venermo M, Kiviluoto O, Partio EK, Konttinen Y, et al. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J Gen Virol. 2000;81(4):1017–25.PubMedCrossRefGoogle Scholar
  77. 77.
    Peterlana D, Puccetti A, Beri R, Ricci M, Simeoni S, Borgato L, et al. The presence of parvovirus B19 VP and NS1 genes in the synovium is not correlated with rheumatoid arthritis. J Rheumatol. 2003;30(9):1907–10.PubMedGoogle Scholar
  78. 78.
    Hajeer AH, MacGregor AJ, Rigby AS, Ollier WER, Carthy D, Silman AJ. Influence of previous exposure to human parvovirus B19 infection in explaining susceptibility to rheumatoid arthritis: an analysis of disease-discordant twin pairs. Ann Rheum Dis. 1994;53(2):137–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Cope AP, Jones A, Brozovic M, Shafi MS, Maini RN. Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis. 1992;51:803–4.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Severin MC, Levy Y, Shoenfeld Y. Systemic lupus erythematosus and parvovirus B-19: casual coincidence or causative culprit? Clin Rev Allergy Immunol. 2003;25(1):41–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Bengtsson A, Widell A, Elmstahl S, Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis. 2000;59(1):64–6.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Pugliese A, Beltramo T, Torre D, Roccatello D. Parvovirus B19 and immune disorders. Cell Biochem Funct. 2008;25(6):639–41.CrossRefGoogle Scholar
  83. 83.
    Hod T, Zandman-Goddard G, Langevitz P, Rudnic H, Grossman Z, Rotman-Pikielny P, et al. Does parvovirus infection have a role in systemic lupus erythematosus? Immunol Res. 2017;65(2):447–53.PubMedCrossRefGoogle Scholar
  84. 84.
    Nesher G, Osborn TG, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum. 1995;24(5):297–303.PubMedCrossRefGoogle Scholar
  85. 85.
    Rowe IF, Deans AC, Midgley J, Anderson MJ, Keat AC. Parvovirus infection in hospital practice. Rheumatology. 1987;26(1):13–6.CrossRefGoogle Scholar
  86. 86.
    Abeygunasekara SC, Peat D, Ross CN. Endocapillary glomerulonephritis secondary to human parvovirus B19 presenting with nephrotic syndrome: a report of two cases and a review of the literature. Ren Fail. 2010;32(7):880–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018;27(4):572–83.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 2003;48(7):1939–47.CrossRefGoogle Scholar
  89. 89.
    Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40(1):103–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Rigante D, Bosco A, Esposito S. The etiology of juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2015;49(2):253–61.PubMedCrossRefGoogle Scholar
  91. 91.
    Angelini F, Cancrini C, Colavita M, Panei P, Concato C, Romiti ML, et al. Role of parvovirus B19 infection in juvenile chronic arthritis. Is more investigation needed? Clin Exp Rheumatol. 2003;21(5):684.PubMedGoogle Scholar
  92. 92.
    Weissbrich B, Süß-Fröhlich Y, Girschick HJ. Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis. Arthritis Res Ther. 2007;9(4):R82.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Oǧuz F, Akdeniz C, Ünüvar E, Küçükbasmaci Ö, Sidal M. Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J Paediatr Child Health. 2002;38(4):358–62.PubMedCrossRefGoogle Scholar
  94. 94.
    Gonzalez B, Larrañaga C, León O, Díaz P, Miranda M, Barría M, et al. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis. J Rheumatol. 2007;34(6):1336–40.PubMedGoogle Scholar
  95. 95.
    Nikkari S, Mertsola J, Korvenranta H, Vainionpää R, Toivanen P. Wegener’s granulomatosis and parvovirus B19 infection. Arthritis Rheum. 1994;37(11):1707–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Chou T-NK, Hsu T-C, Chen R-M, Lin L-I, Tsay GJ. Parvovirus B19 infection associated with the production of antineutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL). Lupus. 2000;9(7):551–4.PubMedCrossRefGoogle Scholar
  97. 97.
    Corman L, Dolson D. Polyarteritis nodosa and parvovirus B19 infection. Lancet. 1992;339(8791):491.PubMedCrossRefGoogle Scholar
  98. 98.
    Finkel TH, Leung DYM, Harbeck RJ, Gelfand EW, Török TJ, Zaki SR, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet. 1994;343(8908):1255–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum. 1999;42(6):1255–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Álvarez-Lafuente R, Fernández-Gutiérrez B, Jover JA, Júdez E, Loza E, Clemente D, et al. Human parvovirus B19, varicella zoster virus, and human herpesvirus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real-time polymerase chain reaction. Ann Rheum Dis. 2005;64(5):780–2.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Eden A, Mahr A, Servant A, Radjef N, Amard S, Mouthon L, et al. Lack of association between B19 or V9 erythrovirus infection and ANCA-positive vasculitides: a case-control study. Rheumatology. 2003;42(5):660–4.PubMedCrossRefGoogle Scholar
  102. 102.
    Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S, Matsunaga Y. Human parvovirus B19 infection in Kawasaki disease. Lancet. 1994;344(8914):58–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum. 1991;34(10):1319–24.PubMedCrossRefGoogle Scholar
  104. 104.
    Buchwald D, Goldenberg DL, Sullivan JL, Komaroff AL. The “chronic, active Epstein-Barr virus infection” syndrome and primary fibromyalgia. Arthritis Rheum. 1987;30(10):1132–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Kerr JR, Coyle PV, DeLeys RJ, Patterson CC. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection. J Med Virol. 1996;48(1):68–75.PubMedCrossRefGoogle Scholar
  106. 106.
    Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F. Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol. 2009;28(3):305–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Ilaria RL, Komaroff AL, Fagioli LR, Moloney WC, True CA, Naides SJ. Absence of parvovirus b19 infection in chronic fatigue syndrome. Arthritis Rheum. 1995;38(5):638–41.PubMedCrossRefGoogle Scholar
  108. 108.
    Mawle AC, Nisenbaum R, Dobbins JG, Gary HE, Stewart JA, Reyes M, et al. Seroepidemiology of chronic fatigue syndrome: a case-control study. Clin Infect Dis. 1995;21(6):1386–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Narváez J, Nolla J-M, Valverde J. No serological evidence that fibromyalgia is linked with exposure to human parvovirus B19. Joint Bone Spine. 2005;72(6):592–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Pouchot J, Ouakil H, Debin ML, Vinceneux P. Adult Still’s disease associated with acute human parvovirus B19 infection. Lancet. 1993;341(8855):1280–1.PubMedCrossRefGoogle Scholar
  111. 111.
    Owren PA. Congenital hemolytic jaundice. The pathogenesis of the “Hemolytic Crisis”. Blood. 1948;3(3):231–48.PubMedGoogle Scholar
  112. 112.
    Maini R, Edelsten C. Uveitis associated with parvovirus infection. Br J Ophthalmol. 1999;83(12):1403–4.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Groen-Hakan F, Babu K, Tugal-Tutkun I, Pathanapithoon K, de Boer JH, Smith JR, et al. Challenges of diagnosing viral anterior uveitis. Ocul Immunol Inflamm. 2017;25(5):710–20.PubMedCrossRefGoogle Scholar
  114. 114.
    Ferri C, Zakrezewska K, Longombardo G, Giuggioli D, Sotrino FA, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol. 1999;17(8):718–20.PubMedGoogle Scholar
  115. 115.
    Zakrzewska K, Corcioli F, Carlsen KM, Giuggioli D, Fanci R, Rinieri A, et al. Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology. 2009;52(5):279–82.PubMedCrossRefGoogle Scholar
  116. 116.
    Cakirca M, Karatoprak C, Ugurlu S, Zorlu M, Kıskaç M, Çetin G. Parvovirus B19 infection as a cause of acute myositis in an adult. Rev Bras Reumatol. 2015;55(2):185–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Neil Crowson A, Magro CM, Dawood MR. A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol. 2000;27(10):505–15.CrossRefGoogle Scholar
  118. 118.
    Lucas RM, Mcmichael AJ. Public Health Classics Association or causation: evaluating links between “environment and disease” [Internet]. Vol. 83, Bulletin of the World Health Organization; 2005 [cited 2018 Sep 25]. Available from:
  119. 119.
    Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12(1):14.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev. 1995;9(3):176–82.PubMedCrossRefGoogle Scholar
  121. 121.
    Brown KE, Young NS. Parvoviruses and bone marrow failure. Stem Cells. 1996;14(2):151–63.PubMedCrossRefGoogle Scholar
  122. 122.
    Anderson MJ, Davis LR, Hodgson J, Jones SE, Murtaza L, Pattison JR, et al. Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two-year period. J Clin Pathol. 1982;35(7):744–9.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Means RT. Pure red cell aplasia. Hematology. 2016;2016(1):51–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Furukawa M, Kaji K, Masuda H, Ozaki K, Asada S, Koizumi A, et al. Severe aplastic anemia following parvovirus B19-associated acute hepatitis. Case Rep Hepatol. 2017;2017:1–5.CrossRefGoogle Scholar
  125. 125.
    Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia - a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30(5):436–43.PubMedCrossRefGoogle Scholar
  126. 126.
    Papadakis V, Katsibardi K, Giannaki M, Drakou C. Autoimmune hemolytic anemia with concurrent acute parvovirus B19 infection in a heterozygous for sickle cell patient and literature review. Pediatr Hematol Oncol. 2013;30(5):455–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Marco H, Guermah I, Matas L, Hernández A, Navarro M, Lopez D, et al. Postinfectious glomerulonephritis secondary to Erythrovirus B19 (Parvovirus B19): case report and review of the literature. Clin Nephrol. 2016;85(04):238–44.PubMedCrossRefGoogle Scholar
  128. 128.
    Hara S, Hirata M, Ito K, Mizushima I, Fujii H, Yamada K, et al. Post-infectious acute glomerulonephritis with podocytopathy induced by parvovirus B19 infection. Pathol Int. 2018;68(3):190–5.PubMedCrossRefGoogle Scholar
  129. 129.
    Murer L, Zacchello G, Bianchi D, Dall’Amico R, Montini G, Andreetta B, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol. 2000;11(6):1132–7.PubMedGoogle Scholar
  130. 130.
    Chandra P, Kopp JB. Viruses and collapsing glomerulopathy: a brief critical review. Clin Kidney J. 2013;6(1):1–5.PubMedCrossRefGoogle Scholar
  131. 131.
    Ieiri N, Hotta O, Taguma Y. Characteristics of acute glomerulonephritis associated with human parvovirus B19 infection. Clin Nephrol. 2005;64(4):249–57.PubMedCrossRefGoogle Scholar
  132. 132.
    Dettmar AK, Oh J. Infection-related focal segmental glomerulosclerosis in children. Biomed Res Int. 2016;2016:7351964.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    D’Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol. 2013;8(3):399–406.PubMedCrossRefGoogle Scholar
  134. 134.
    Besse W, Mansour S, Jatwani K, Nast CC, Brewster UC. Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation. BMC Nephrol. 2016;17(1):125.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Waldman M, Kopp JB. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol. 2007;2(Supplement 1):S47–56.PubMedCrossRefGoogle Scholar
  136. 136.
    Mihály I, Trethon A, Arányi Z, Lukács A, Kolozsi T, Prinz G, et al. Observations on human parvovirus B19 infection diagnosed in 2011. Orv Hetil. 2012;153(49):1948–57.PubMedCrossRefGoogle Scholar
  137. 137.
    Bihari C, Rastogi A, Saxena P, Rangegowda D, Chowdhury A, Gupta N, et al. Parvovirus B19 associated hepatitis. Hepat Res Treat. 2013;2013:1–9.Google Scholar
  138. 138.
    Langnas AN, Markin RS, Cattral MS, Naides SJ. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology. 1995;22(6):1661–5.PubMedGoogle Scholar
  139. 139.
    Rauff B, Idrees M, Shah SAR, Butt S, Butt AM, Ali L, et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011;8(1):87.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Mogensen TH, Jensen JMB, Hamilton-Dutoit S, Larsen CS. Chronic hepatitis caused by persistent parvovirus B19 infection. BMC Infect Dis. 2010;10:246.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Toan NL, Song LH, Kremsner PG, Duy DN, Binh VQ, Duechting A, et al. Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus infection. J Hepatol. 2006;45(3):361–9.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Hsu T-C, Chen T-Y, Lin M-C, Tzang B-S, Tsay GJ. Human parvovirus B19 infection in patients with chronic hepatitis B or hepatitis C infection. J Gastroenterol Hepatol. 2005;20(5):733–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Wang C, Heim A, Schlaphoff V, Suneetha PV, Stegmann KA, Jiang H, et al. Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. J Med Virol. 2009;81(12):2079–88.PubMedCrossRefGoogle Scholar
  144. 144.
    Kerr JR. The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol. 2016;69(4):279–91.PubMedCrossRefGoogle Scholar
  145. 145.
    Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17):2073–82.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca H-P, et al. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail. 2016;18(12):1430–41.PubMedCrossRefGoogle Scholar
  147. 147.
    Modrow S. Parvovirus B19: the causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard? In: Schultheiss HP, Kapp JF, Grötzbach G, editors. Chronic viral and inflammatory cardiomyopathy. Berlin/Heidelberg: Springer; 2008. p. 63–82. PMID:16329658;
  148. 148.
    Bock C-T, Düchting A, Utta F, Brunner E, Sy BT, Klingel K, et al. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol. 2014;6(4):183.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Dennert R, Velthuis S, Schalla S, Eurlings L, Van Suylen RJ, Van Paassen P, et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;15(2):193–201.PubMedCrossRefGoogle Scholar
  150. 150.
    Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48(12):1713–23.PubMedCrossRefGoogle Scholar
  151. 151.
    Watanabe T, Kawashima H. Acute encephalitis and encephalopathy associated with human parvovirus B19 infection in children. World J Clin Pediatr. 2015;4(4):126–34.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Barah F, Vallely PJ, Cleator GM, Kerr JR. Neurological manifestations of human parvovirus B19 infection. Rev Med Virol. 2003;13(3):185–99.PubMedCrossRefGoogle Scholar
  153. 153.
    Fullerton HJ, Luna JM, Wintermark M, Hills NK, Tokarz R, Li Y, et al. Parvovirus B19 infection in children with arterial ischemic stroke. Stroke. 2017 Oct;48(10):2875–7.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Ogunsile FJ, Currie KL, Rodeghier M, Kassim A, DeBaun MR, Sharma D. History of parvovirus B19 infection is associated with silent cerebral infarcts. Pediatr Blood Cancer. 2018;65(1):e26767.CrossRefGoogle Scholar
  155. 155.
    Bilge I, Sadıkoğlu B, Emre S, Şirin A, Aydın K, Tatlı B. Central nervous system vasculitis secondary to parvovirus B19 infection in a pediatric renal transplant patient. Pediatr Nephrol. 2005;20(4):529–33.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Hobbs JA. Parvovirus B19–brain interactions: infection, autoimmunity, or both? J Clin Virol. 2007;38(4):364–5.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Neu N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol. 2015;42(1):77–103.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ. 1990;300(6733):1166–70.CrossRefGoogle Scholar
  159. 159.
    Valeur-Jensen AK, Pedersen CB, Westergaard T, Jensen IP, Lebech M, Andersen PK, et al. Risk factors for parvovirus B19 infection in pregnancy. J Am Med Assoc. 1999;281(12):1099–105.CrossRefGoogle Scholar
  160. 160.
    Crane J, Mundle W, Boucoiran I, Gagnon R, Bujold E, Basso M, et al. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2014;36(12):1107–16.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Bonvicini F, Bua G, Gallinella G. Parvovirus B19 infection in pregnancy — awareness and opportunities. Curr Opin Virol. 2017;27:8–14.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res. 2017;109(5):311–23.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Melamed N, Whittle W, Kelly EN, Windrim R, Seaward PGR, Keunen J, et al. Fetal thrombocytopenia in pregnancies with fetal human parvovirus-B19 infection. Am J Obstet Gynecol. 2015;212(6):793.e1–8.CrossRefGoogle Scholar
  164. 164.
    Markenson GR, Yancey MK. Parvovirus B 19 infections in pregnancy. Semin Perinatol. 1998;22(4):309–17.PubMedCrossRefGoogle Scholar
  165. 165.
    Abbasi N, Johnson JA, Ryan G. Fetal anemia. Ultrasound Obstet Gynecol. 2017;50(2):145–53.PubMedCrossRefGoogle Scholar
  166. 166.
    Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24(7):513–8.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Jordan JA, Deloia JA. Globoside expression within the human placenta. Placenta. 1999;20(1):103–8.PubMedCrossRefGoogle Scholar
  168. 168.
    Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 cytodeath antibody. Placenta. 2002;23(7):547–53.PubMedCrossRefGoogle Scholar
  169. 169.
    Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol. 2006;21(4):421–35.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Nicolaides KH, Thilaganathan B, Rodeck CH, Mibashan RS. Erythroblastosis and reticulocytosis in anemic fetuses. Am J Obstet Gynecol. 1988;159(5):1063–5.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Bascietto F, Liberati M, Murgano D, Buca D, Iacovelli A, Flacco ME, et al. Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;52(5):569–76.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Moise KJ. Red blood cell alloimmunization in pregnancy. Semin Hematol. 2005;42(3):169–78.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, et al. Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010;4(4):63–6.PubMedPubMedCentralGoogle Scholar
  174. 174.
    Fairley CK, Miller E, Smoleniec JS, Caul OE. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995;346(8986):1335–7.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Selbing A, Josefsson A, Dahle L, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345(8950):660–1.PubMedCrossRefGoogle Scholar
  176. 176.
    Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968–77.PubMedCrossRefGoogle Scholar
  177. 177.
    Lamont R, Sobel J, Vaisbuch E, Kusanovic J, Mazaki-Tovi S, Kim S, et al. Parvovirus B19 infection in human pregnancy. BJOG An Int J Obstet Gynaecol. 2011;118(2):175–86.CrossRefGoogle Scholar
  178. 178.
    Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med. 2005;33(6):561–3.PubMedCrossRefGoogle Scholar
  179. 179.
    Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926–33.PubMedCrossRefGoogle Scholar
  180. 180.
    Saunders PW, Reid MM, Cohen BJ. Human parvovirus-induced cytopenias: a report of five cases. Br J Haematol. 1986;63(2):407–10.PubMedCrossRefGoogle Scholar
  181. 181.
    Boruchoff SE, Woda BA, Pihan GA, Durbin WA, Burstein D, Blacklow NR. Parvovirus B19-associated hemophagocytic syndrome. Arch Intern Med. 1990;150(4):897–9.PubMedCrossRefGoogle Scholar
  182. 182.
    Meyer O, Kahn MF, Grossin M, Ribard P, Belmatoug N, Morinet F, et al. Parvovirus B19 infection can induce histiocytic necrotizing lymphadenitis (Kikuchi’s disease) associated with systemic lupus erythematosus. Lupus. 1991;1(1):37–41.PubMedCrossRefGoogle Scholar
  183. 183.
    Foreman NK, Oakhill A, Caul EO. Parvovirus-associated thrombocytopenic purpura. Lancet. 1988;2(8625):1426–7.PubMedCrossRefGoogle Scholar
  184. 184.
    Murray JC, Morad AB. Childhood autoimmune neutropenia and human parvovirus B19. Am J Hematol. 1994;47(4):336.PubMedCrossRefGoogle Scholar
  185. 185.
    de la Rubia J, Moscardó F, Arriaga F, Monteagudo E, Carreras C, Marty ML. Acute parvovirus B19 infection as a cause of autoimmune hemolytic anemia. Haematologica. 2000;85(9):995–7.PubMedGoogle Scholar
  186. 186.
    Kalish RA, Knopf AN, Gary GW, Canoso JJ. Lupus-like presentation of human parvovirus B19 infection. J Rheumatol. 1992;19(1):169–71.PubMedGoogle Scholar
  187. 187.
    Lefrère JJ, Couroucé AM, Soulier JP, Cordier MP, Guesne Girault MC, Polonovski C, et al. Henoch-Schönlein purpura and human parvovirus infection. Pediatrics. 1986;78(1):183–4.PubMedGoogle Scholar
  188. 188.
    Nigro G, Zerbini M, Krzysztofiak A, Gentilomi G, Porcaro MA, Mango T, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet. 1994;343(8908):1260–1.PubMedCrossRefGoogle Scholar
  189. 189.
    Jacobson SK, Daly JS, Thorne GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis. 1997;24(6):1048–51.PubMedCrossRefGoogle Scholar
  190. 190.
    Samii K, Cassinotti P, de Freudenreich J, Gallopin Y, Le Fort D, Stalder H. Acute bilateral carpal tunnel syndrome associated with human parvovirus B19 infection. Clin Infect Dis. 1996;22(1):162–4.PubMedCrossRefGoogle Scholar
  191. 191.
    Perandones CE, Colmegna I, Arana RM. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol. 2005;32(2):389–90.PubMedGoogle Scholar
  192. 192.
    Ferri C, Longombardo G, Azzi A, Zakrzewska K. Parvovirus B19 and systemic sclerosis. Clin Exp Rheumatol. 1999;17(2):267–8.PubMedGoogle Scholar
  193. 193.
    Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis. 1995;21(2):430–2.PubMedCrossRefGoogle Scholar
  194. 194.
    Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. J Rheumatol. 1996;23(7):1180–5.PubMedGoogle Scholar
  195. 195.
    Barco S, Bertolino G, Ambaglio C, Mangione F. Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman. Hum Pathol. 2013;44(6):1192–3.PubMedCrossRefGoogle Scholar
  196. 196.
    Moudgil A, Nast CC, Bagga A, Wei L, Nurmamet A, Cohen AH, et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int. 2001;59(6):2126–33.PubMedCrossRefGoogle Scholar
  197. 197.
    Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S. Human parvovirus B19 infection associated with acute hepatitis. Lancet. 1996;347(9005):868–9.PubMedCrossRefGoogle Scholar
  198. 198.
    Arista S, De Grazia S, Di Marco V, Di Stefano R, Craxì A. Parvovirus B19 and “cryptogenic” chronic hepatitis. J Hepatol. 2003;38(3):375–6.PubMedCrossRefGoogle Scholar
  199. 199.
    Sokal EM, Melchior M, Cornu C, Vandenbroucke AT, Buts JP, Cohen BJ, et al. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet. 1998;352(9142):1739–41.PubMedCrossRefGoogle Scholar
  200. 200.
    Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol. 1998;93(3):468–70.PubMedCrossRefGoogle Scholar
  201. 201.
    Saint-Martin J, Choulot JJ, Bonnaud E, Morinet F. Myocarditis caused by parvovirus. J Pediatr. 1990;116(6):1007–8.PubMedCrossRefGoogle Scholar
  202. 202.
    Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D’Amati G, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis. 2000;31(1):65–9.PubMedCrossRefGoogle Scholar
  203. 203.
    Lotze U, Egerer R, Tresselt C, Glück B, Dannberg G, Stelzner A, et al. Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med Microbiol Immunol. 2004;193(2–3):75–82.PubMedCrossRefGoogle Scholar
  204. 204.
    Kühl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CPL, Seeberg B, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108(8):945–50.PubMedCrossRefGoogle Scholar
  205. 205.
    Watanabe T, Satoh M, Oda Y. Human parvovirus B19 encephalopathy. Arch Dis Child. 1994;70(1):71.PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Heegaard ED, Peterslund NA, Hornsleth A. Parvovirus B19 infection associated with encephalitis in a patient suffering from malignant lymphoma. Scand J Infect Dis. 1995;27(6):631–3.PubMedCrossRefGoogle Scholar
  207. 207.
    Okumura A, Ichikawa T. Aseptic meningitis caused by human parvovirus B19. Arch Dis Child. 1993;68(6):784–5.PubMedPubMedCentralCrossRefGoogle Scholar
  208. 208.
    Guidi B, Bergonzini P, Crisi G, Frigieri G, Portolani M. Case of stroke in a 7-year-old male after parvovirus B19 infection. Pediatr Neurol. 2003;28(1):69–71.PubMedCrossRefGoogle Scholar
  209. 209.
    Hsu D, Sandborg C, Hahn JS. Frontal lobe seizures and uveitis associated with acute human parvovirus B19 infection. J Child Neurol. 2004;19(4):304–6.PubMedCrossRefGoogle Scholar
  210. 210.
    Fong CY, de Sousa C. Childhood chorea-encephalopathy associated with human parvovirus B19 infection. Dev Med Child Neurol. 2006;48(6):526–8.PubMedCrossRefGoogle Scholar
  211. 211.
    Shimizu Y, Ueno T, Komatsu H, Takada H, Nunoue T. Acute cerebellar ataxia with human parvovirus B19 infection. Arch Dis Child. 1999;80(1):72–3.PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Scheibe F, Hofmann J, Ruprecht K. Parainfectious myelitis associated with parvovirus B19 infection. J Neurol. 2010;257(9):1557–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Denning DW, Amos A, Rudge P, Cohen BJ. Neuralgic amyotrophy due to parvovirus infection. J Neurol Neurosurg Psychiatry. 1987;50(5):641–2.PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Minohara Y, Koitabashi Y, Kato T, Nakajima N, Murakami H, Masaki H, et al. A case of Guillain-Barré syndrome associated with human parvovirus B19 infection. J Infect. 1998;36(3):327–8.PubMedCrossRefGoogle Scholar
  215. 215.
    Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984;2(8410):1033–4.PubMedCrossRefGoogle Scholar
  216. 216.
    Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316(4):183–6.PubMedCrossRefGoogle Scholar
  217. 217.
    Gray ES, Davidson RJ, Anand A. Human parvovirus and fetal anaemia. Lancet. 1987;1(8542):1144.PubMedCrossRefGoogle Scholar
  218. 218.
    Segata M, Chaoui R, Khalek N, Bahado-Singh R, Paidas MJ, Mari G. Fetal thrombocytopenia secondary to parvovirus infection. Am J Obstet Gynecol. 2007;196(1):61.e1–4.CrossRefGoogle Scholar
  219. 219.
    Respondek M, Bratosiewicz J, Pertyński T, Liberski PP. Parvovirus particles in a fetal-heart with myocarditis: ultrastructural and immunohistochemical study. Arch Immunol Ther Exp. 1997;45(5–6):465–70.Google Scholar
  220. 220.
    Van Elsacker-Niele AM, Salimans MM, Weiland HT, Vermey-Keers C, Anderson MJ, Versteeg J. Fetal pathology in human parvovirus B19 infection. Br J Obstet Gynaecol. 1989;96(7):768–75.PubMedCrossRefGoogle Scholar
  221. 221.
    Katz VL, McCoy MC, Kuller JA, Hansen WF. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol. 1996;13(1):43–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Martin Brom
    • 1
    • 2
  • Carlos Edgardo Perandones
    • 1
    • 3
  1. 1.Fundación FavaloroBuenos AiresArgentina
  2. 2.Hospital Italiano de Buenos AiresBuenos AiresArgentina
  3. 3.FLENI (Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia)Buenos AiresArgentina

Personalised recommendations